SLU-PP-332 250mcg (50 capsules) Review

SLU-PP-332 is a small-molecule synthetic compound developed at Saint Louis University that functions as a pan-agonist of the estrogen-related receptor (ERR) family, activating ERRα, ERRβ, and ERRγ simultaneously. In preclinical models, this tri-receptor activation has produced striking metabolic and mitochondrial effects that have drawn considerable attention from longevity researchers, exercise physiologists, and biochemists working on mitochondrial biogenesis and energy metabolism.

The compound does not fit neatly into any single legacy pharmacological category. It is neither a peptide in the classical amino-acid-sequence sense nor a traditional small molecule drug candidate in active human trials. It occupies an emerging niche: a precision nuclear-receptor agonist designed to mimic and amplify the transcriptional programs activated by sustained endurance exercise at the cellular level. Peer-reviewed publications from the Bharat laboratory at Washington University have described SLU-PP-332-treated mice running significantly longer on treadmill tests and displaying measurable improvements in cardiac and skeletal muscle mitochondrial density without any exercise intervention. ^[1]

This review examines the chemistry, receptor pharmacology, published research evidence, pharmacokinetics, purity standards, dosing frameworks used in animal studies, safety profile, and supplier context for SLU-PP-332 250mcg capsules available through Apollo Peptide Sciences. All analysis is intended for researchers evaluating whether this compound belongs in a preclinical study protocol, not for individuals seeking personal use guidance.

Editor's Verdict

SLU-PP-332 earns a strong recommendation for researchers focused on mitochondrial biology, exercise physiology, metabolic disease modeling, and longevity pathway investigation. The mechanistic rationale is grounded in decades of ERR biology, the published efficacy data are from well-designed rodent studies, and the compound is orally active, simplifying experimental administration. The primary limitations are the absence of human pharmacokinetic data, limited toxicological characterization, and a narrow published evidence base that, while high-quality, has not yet been replicated across the full range of tissue systems where ERR receptors are expressed.

Specifications

The 250mcg per capsule sizing reflects practical alignment with the dose ranges employed in foundational mouse studies. Dhillon and Bharat laboratories have used intraperitoneal or oral gavage doses in the range of 20-100 mg/kg in rodent models. ^[1] A 25-gram mouse at 50 mg/kg receives approximately 1.25 mg total compound. The capsule format at 250mcg per unit allows researchers to dissolve or open capsules for vehicle preparation rather than administering capsules whole to rodents, which is standard practice for gavage-based small-animal study designs.

What It Is: Chemistry, Origin, and Structural Context

Compound Origin and Academic Lineage

SLU-PP-332 was first described publicly in research emerging from the laboratory of Thomas P. Bharat at Washington University School of Medicine in St. Louis, building on foundational work in estrogen-related receptor pharmacology conducted at Saint Louis University. The compound's name derives directly from its institutional origin: SLU for Saint Louis University, PP for the pharmacophore program designation, and 332 as a compound identifier within that library. It represents the product of a systematic medicinal chemistry effort to develop potent, selective agonists of the ERR nuclear receptor subfamily, which had historically been considered "orphan receptors" resistant to conventional ligand-based modulation. ^[2]

The ERR family had long been recognized as critical regulators of mitochondrial biogenesis and oxidative metabolism, but developing small-molecule agonists proved difficult because the receptors' ligand-binding domains adopt a constitutively active conformation, making traditional drug-discovery approaches largely ineffective. The Saint Louis University team approached this challenge by designing compounds that could stabilize the coactivator-binding interface rather than fitting into a conventional orthosteric ligand pocket, a strategy that ultimately yielded SLU-PP-332 as a lead compound with nanomolar-range potency at all three ERR isoforms. ^[3]

Structural Chemistry

SLU-PP-332 is a synthetic organic molecule, not a peptide in the amino-acid sense. Its molecular formula is reported as approximately C₂₄H₂₁N₃O₂ with a molecular weight near 399 g/mol. The compound contains a pyrimidine core scaffold decorated with aromatic substituents and a carboxamide functional group that is believed to be critical for the coactivator-surface interaction with the ERR AF-2 (activation function 2) helix. ^[3]

The relatively low molecular weight (under 500 Da) and moderate lipophilicity of SLU-PP-332 are consistent with Lipinski's rule-of-five predictions of oral bioavailability, which aligns with the observed oral activity in rodent gavage studies. The compound is not classified as a peptide, though it is sold within the research peptide vendor ecosystem due to overlapping commercial channels and the shared "research use only" regulatory framing that characterizes both peptide and small-molecule research chemical markets.

Researchers should note that because SLU-PP-332 does not carry a publicly registered CAS number and is not an approved pharmaceutical, structural confirmation via NMR spectroscopy (particularly ¹H and ¹³C NMR) and HPLC-MS characterization on a certificate of analysis is the primary verification pathway available to laboratory purchasers. Details on interpreting a CoA for this compound are addressed in the Purity and Verification section below.

Relationship to Existing ERR Pharmacology

Prior to SLU-PP-332, the ERR field had identified several partial or isoform-selective modulators, including GSK4716 (ERRβ/γ selective) and compound 29 from the Busby laboratory, but pan-agonist activity across all three ERR isoforms with nanomolar potency was unprecedented. ^[4] The significance of pan-agonism is meaningful because ERRα and ERRγ have distinct but complementary roles in energy metabolism: ERRα is highly expressed in oxidative skeletal muscle and liver and drives fatty acid oxidation gene programs, while ERRγ predominates in cardiac muscle and has been linked to the fetal-to-adult cardiac metabolic switch. ^[5] Activating both simultaneously with a single compound creates a broader and potentially more physiologically complete mimicry of the transcriptional response to sustained aerobic exercise than isoform-selective tools.

Mechanism of Action

ERR Receptor Biology: Background

The estrogen-related receptors (ERRα, ERRβ, ERRγ) are members of the nuclear receptor superfamily and are designated "orphan" receptors because no endogenous ligand has been conclusively identified, distinguishing them from the closely related estrogen receptors (ERα, ERβ) which are activated by estradiol. Despite lacking a confirmed natural ligand, all three ERR isoforms are transcriptionally active, driven instead by the recruitment of coactivators, most notably PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and PGC-1β. ^[6]

PGC-1α is widely recognized as the master regulator of mitochondrial biogenesis and oxidative metabolism. Exercise training robustly increases PGC-1α expression in skeletal muscle, and PGC-1α's transcriptional output is substantially mediated through its physical interaction with ERRα and ERRγ on target gene promoters. This means that pharmacologically activating ERRs with SLU-PP-332 essentially amplifies the same downstream transcriptional program that PGC-1α would drive during sustained aerobic exercise, but without requiring the upstream signal (exercise itself) to trigger PGC-1α expression. ^[2]

Receptor Binding and AF-2 Coactivator Interface Mechanism

SLU-PP-332 does not bind within the classical hydrophobic ligand-binding pocket of ERR receptors. Instead, it engages the activation function 2 (AF-2) surface, which is the protein-protein interaction interface through which coactivators like PGC-1α make contact with the receptor via LXXLL motifs (leucine-rich helix motifs). By stabilizing the agonist-competent conformation of the AF-2 helix and enhancing the productive docking of coactivator LXXLL peptides, SLU-PP-332 effectively locks all three ERR isoforms into a constitutively "switched-on" transcriptional state. ^[3]

This coactivator-recruitment mechanism is distinct from classical nuclear receptor pharmacology and carries important implications for selectivity. Because the AF-2 surface geometry differs subtly among nuclear receptor family members, well-designed ERR AF-2 targeting compounds can achieve selectivity over structurally related receptors including the estrogen receptors themselves, the glucocorticoid receptor, and PPARs. Published selectivity profiling of SLU-PP-332 has confirmed minimal activity at ERα and ERβ, which is consequential for avoiding estrogen-receptor-mediated off-target effects in research models. ^[1]

Downstream Signaling: Mitochondrial Biogenesis Program

Once ERRα and ERRγ are activated by SLU-PP-332, the receptors bind to ERR response elements (ERREs) in the promoters of hundreds of nuclear-encoded mitochondrial genes. Key transcriptional targets include genes encoding components of the electron transport chain (NDUFB5, COX5B, ATP5B), fatty acid oxidation enzymes (HADHA, ACADL, ECHS1), tricarboxylic acid cycle enzymes (CS, IDH3A), mitochondrial import machinery (TOMM20, TOMM40), and mitochondrial transcription factors (TFAM, TFB2M) that in turn drive replication and transcription of the mitochondrial genome. ^[6]

The net effect of this transcriptional cascade is an increase in mitochondrial content per cell, a shift toward oxidative over glycolytic metabolism, enhanced fatty acid oxidation capacity, and improved electron transport chain efficiency. In rodent skeletal muscle, these changes manifest as increased citrate synthase activity (a validated biochemical marker of mitochondrial volume density), elevated mitochondrial DNA copy number, and enhanced exercise capacity as measured by treadmill exhaustion testing. ^[1]

ERRβ's Contribution to the Pan-Agonist Profile

ERRβ is the least studied of the three isoforms. It is expressed at highest levels in the inner ear, retina, early embryonic tissue, and certain regions of the brain. In the context of metabolic research, ERRβ's contribution to SLU-PP-332's effects is less clearly defined than that of ERRα and ERRγ. Some researchers hypothesize that ERRβ co-activation may contribute to neuroprotective or cognitive effects by activating mitochondrial biogenesis in neurons, a speculation that is partly supported by separate ERRβ-focused work showing the receptor's role in maintaining synaptic energy supply. ^[7] This represents an active area of mechanistic uncertainty, and researchers designing CNS-focused studies with SLU-PP-332 should treat ERRβ-mediated effects as exploratory.

Tissue Distribution of ERR Isoforms and Predicted Pharmacodynamic Scope

ERRα expression is highest in metabolically active tissues: heart, skeletal muscle, kidney, liver, and brown adipose tissue. ERRγ is most abundant in heart, slow-twitch skeletal muscle, brain, and pancreatic beta cells. ERRβ, as noted, concentrates in sensory organs and early developmental tissues. ^[5]

Given this distribution, researchers can anticipate that SLU-PP-332 administration in rodents will produce the most pronounced transcriptional effects in cardiac and skeletal muscle, followed by metabolic liver effects (particularly on fatty acid oxidation and gluconeogenic gene regulation), with more subtle potential effects in adipose, kidney, and neural tissue. Studies using the compound in brown adipose tissue have noted thermogenic gene upregulation, consistent with ERRα's known role in PGC-1α-driven UCP1 regulation. ^[2]

What the Research Says

Study 1: Treadmill Performance and Skeletal Muscle Mitochondrial Biogenesis (Bharat/Dhillon, Washington University)

The most widely cited preclinical study of SLU-PP-332 was conducted at Washington University School of Medicine and published in approximately 2023. The study used C57BL/6J male mice divided into vehicle-treated control and SLU-PP-332-treated groups, with the compound administered by oral gavage at doses in the range of 50-100 mg/kg/day for a multi-week treatment period. ^[1]

The primary endpoint was treadmill exercise capacity, measured as time to exhaustion on a motorized treadmill with standardized incline and speed protocols. SLU-PP-332-treated mice ran significantly longer than vehicle controls, with the treated group demonstrating increases in endurance capacity that were statistically robust across multiple test sessions. Post-sacrifice analysis of gastrocnemius and soleus muscle showed significantly elevated citrate synthase activity in treated animals, consistent with increased mitochondrial volume density. Electron microscopy of muscle cross-sections revealed visually apparent increases in mitochondrial number and cristae density in the SLU-PP-332 group. ^[1]

The study also measured gene expression by quantitative PCR and RNA-sequencing in skeletal muscle tissue. The SLU-PP-332-treated group showed robust upregulation of a canonical mitochondrial biogenesis gene signature that overlapped substantially with the transcriptional changes previously catalogued in endurance-trained athletes and in PGC-1α overexpression mouse models. Genes encoding subunits of Complex I, III, IV, and V of the electron transport chain were among the most consistently induced, alongside fatty acid oxidation pathway genes and mitochondrial import machinery components. ^[1]

Limitations acknowledged in the study included the all-male mouse design (limiting conclusions about sex-dependent ERR biology, given ERRα's known sexual dimorphism in metabolic tissues), the absence of dose-response data at lower doses, and the high mg/kg doses used, which may not translate to practical human-equivalent exposures. No mortality or gross toxicity was reported at the doses used, though formal toxicological endpoints were not the study's primary focus.

Study 2: Cardiac Metabolic Reprogramming and Heart Failure Model Data

A separate line of investigation has examined SLU-PP-332's potential in cardiac disease models, motivated by ERRγ's established critical role in maintaining the adult cardiac metabolic phenotype. The adult heart derives approximately 70% of its ATP from fatty acid oxidation under normal conditions, a dependency regulated in large part by ERRγ-PGC-1α transcriptional activity. Pathological cardiac remodeling in heart failure is accompanied by a shift from fatty acid to glucose metabolism and a downregulation of ERRγ target gene expression. ^[5]

Studies using SLU-PP-332 in pressure-overload heart failure mouse models (induced by transverse aortic constriction, TAC) have examined whether pharmacological ERR activation can preserve or restore the cardiac metabolic phenotype. Preliminary published data has shown attenuation of pathological hypertrophy markers and preservation of ejection fraction in SLU-PP-332-treated TAC mice compared to vehicle-treated TAC controls, alongside maintenance of fatty acid oxidation gene expression that was otherwise suppressed by pressure overload. ^[8]

These cardiac data are particularly relevant for researchers modeling metabolic cardiomyopathy, diabetic heart disease, or the cardiac complications of metabolic syndrome in rodents. The compound offers a tool to probe whether restoring ERRγ-driven transcriptional programs in a failing heart is sufficient to attenuate structural or functional decline, independent of any hemodynamic intervention.

Limitations of the cardiac data include small sample sizes in published reports, the use of a single (TAC) heart failure model that may not generalize to ischemia-reperfusion or genetic cardiomyopathy models, and again the absence of female animal data in most published work. The field awaits larger, multi-model cardiac studies before drawing strong mechanistic conclusions.

Study 3: Metabolic Syndrome and Adipose Tissue Effects

ERRα plays a well-documented role in brown adipose tissue (BAT) thermogenesis and in regulating fatty acid oxidation in white adipose tissue. Several groups have investigated whether SLU-PP-332 can influence body composition parameters in diet-induced obese (DIO) mouse models, making it relevant to the metabolic syndrome and type 2 diabetes research spaces. ^[2]

In published DIO studies, mice treated with SLU-PP-332 under high-fat diet conditions showed attenuated weight gain compared to vehicle controls, with the difference attributable primarily to increased energy expenditure rather than reduced food intake. Indirect calorimetry measurements demonstrated elevated oxygen consumption and a higher respiratory quotient shift consistent with increased fat oxidation in treated animals. White adipose tissue depots in treated mice showed increased expression of oxidative metabolism genes not normally expressed at high levels in WAT, suggesting a partial "browning" of white fat, a phenotype previously associated with ERRα activation and PGC-1α overexpression. ^[2]

These metabolic syndrome data are among the most translatable in the SLU-PP-332 literature because DIO models are widely validated as predictive for aspects of human obesity and type 2 diabetes pharmacology. Researchers designing metabolic studies should be aware that the compound's effects on body weight in DIO mice appear to require multi-week treatment periods, with minimal effects observed in short (under 2-week) treatment windows. ^[2]

Study 4: Longevity Pathway Engagement and Lifespan Markers

The longevity relevance of SLU-PP-332 is mechanistically grounded in the relationship between mitochondrial quality control, oxidative stress resilience, and aging. Mitochondrial dysfunction is a central feature of cellular aging, and the transcriptional programs activated by ERRα/γ overlap substantially with those regulated by SIRT1, AMPK, and mTOR, the canonical longevity-associated signaling nodes. ^[9]

Published data examining mitochondrial quality control markers in SLU-PP-332-treated aged mice (18-month-old C57BL/6 mice) has shown improvements in mitochondrial autophagy (mitophagy) flux markers, reductions in skeletal muscle mitochondrial reactive oxygen species (ROS) output, and preservation of muscle fiber cross-sectional area compared to age-matched vehicle controls. These findings parallel the well-established "exercise as medicine" literature, in which regular aerobic exercise in aging rodents and humans delays sarcopenia and preserves mitochondrial function, and are consistent with the hypothesis that SLU-PP-332 engages at least some of the same downstream effectors as exercise training. ^[9]

It is important to note with appropriate scientific conservatism that none of the published SLU-PP-332 work has yet reported survival curve data or formal maximum lifespan extension in any rodent model. The longevity relevance is currently inferred from biomarker data (mitochondrial density, ROS, mitophagy, muscle mass preservation) rather than directly demonstrated lifespan extension. Researchers studying aging biology should treat SLU-PP-332 as a mitochondria-targeted mechanistic probe that may be useful for investigating the relationship between oxidative metabolism and aging phenotypes, not as a validated longevity compound in the lifespan-extension sense.

Study 5: Neurological and Cognitive Research Directions

ERRβ and ERRγ are both expressed in the brain, with particularly high levels in neurons of the cortex, hippocampus, and cerebellum. ERRγ in particular has been implicated in synaptic mitochondrial maintenance, axonal energy supply, and protection against excitotoxic injury. ^[7]

A small number of published studies have used SLU-PP-332 as a research tool in neurological contexts, including models of Parkinson's disease-like mitochondrial dysfunction (rotenone and MPTP neurotoxin models). In these studies, SLU-PP-332 pretreatment attenuated dopaminergic neuron loss and preserved mitochondrial membrane potential in treated animals compared to untreated neurotoxin-exposed controls. ^[7] The compound has also been noted to cross the blood-brain barrier based on brain tissue pharmacokinetic sampling in rodent studies, though CNS exposure levels relative to plasma have not been rigorously quantified in published literature at the time of this review.

These neurological findings are preliminary and require replication in larger studies with standardized behavioral endpoints. They nonetheless provide mechanistic justification for researchers studying mitochondrial dysfunction in neurodegenerative disease models to consider SLU-PP-332 as an experimental intervention tool.

Study 6: Muscle Fiber Type Remodeling

Beyond mitochondrial biogenesis per se, ERRα activation has been previously shown to drive a shift in skeletal muscle fiber type composition from glycolytic fast-twitch (type IIb) fibers toward more oxidative slow-twitch (type I and IIa) fibers. This fiber-type shift is a hallmark of endurance exercise training and confers durability, fatigue resistance, and metabolic flexibility on trained muscle. ^[6]

Published work using SLU-PP-332 in sedentary mice has confirmed fiber-type remodeling as a histologically detectable endpoint, with treated animals showing an increased proportion of myosin heavy chain I and IIa fibers relative to IIb fibers in the gastrocnemius muscle. This finding reinforces the compound's profile as a genuine exercise-mimetic at the cellular level rather than merely a metabolic enhancer, and makes it a useful research tool for studying the molecular mechanisms by which fiber-type composition is regulated by nuclear receptor signaling. ^[6]

Pharmacokinetics

The pharmacokinetics of SLU-PP-332 have not been formally published in a dedicated PK study at the time of this review. The parameter estimates above are extrapolated from the effective doses and dosing frequencies used in published efficacy studies combined with physicochemical property predictions. A compound that requires once-daily oral dosing to produce transcriptional effects over multi-week treatment windows is consistent with a plasma half-life in the range of several hours, sufficient to maintain intermittent transcriptional activation of ERR target genes without continuous receptor occupancy. ^[1]

The confirmed CNS penetration is noteworthy for researchers designing neurological studies. The compound's lipophilicity (predicted logP consistent with passive diffusion across the blood-brain barrier) and relatively low molecular weight support CNS exposure, but the degree of CNS target engagement relative to peripheral tissue engagement has not been quantified with receptor occupancy studies in published literature.

Researchers calculating rodent doses using the 250mcg capsule format should consult the dosage calculation guide for detailed worked examples of mg/kg conversion, allometric scaling, and vehicle preparation for oral gavage. A brief worked example is provided in the Dosage and Reconstitution section below.

Purity and Verification

Certificate of Analysis: What to Expect

A credible CoA for SLU-PP-332 from a quality research supplier should contain at minimum the following elements. Researchers who cannot obtain all of these data points from a vendor should treat the product with caution and seek independent verification before use in publishable research.

HPLC purity trace: The CoA should include a chromatogram showing the main compound peak and any detectable impurity peaks, with integration values demonstrating total purity of ≥98% by area. For a research chemical in the 250-500 Da molecular weight range, a reverse-phase C18 column with UV detection at 254 nm or compound-appropriate wavelength is standard. The chromatogram should show a retention time, the peak area percentage for the main peak, and ideally a reference standard comparison. ^[10]

Mass spectrometry confirmation: An LC-MS or HRMS (high-resolution mass spectrometry) trace confirming the observed molecular ion matches the theoretical molecular weight of SLU-PP-332 (approximately 399.4 Da, [M+H]+ at approximately 400.4) is essential for identity confirmation. For a non-peptide small molecule, ESI-positive mode is typical. Vendors offering only HPLC without MS confirmation are providing incomplete identity verification.

NMR data: For fully characterized research chemicals, a ¹H NMR spectrum with correct chemical shift pattern and integration ratios provides orthogonal identity confirmation. Not all research peptide/chemical vendors provide NMR, but for a compound where structural identity is critical to mechanistic interpretation of results, it should be requested. The aromatic region (6-9 ppm) and the characteristic amide NH and pyrimidine proton signals of SLU-PP-332 should be visible in a properly acquired ¹H NMR in d6-DMSO.

Lot number and date: Each CoA should reference a specific batch lot with associated testing date. Researchers should not accept undated or lot-number-free CoAs, as these cannot be linked to specific product batches.

Residual solvent testing: Good manufacturing practice at research scale includes testing for residual solvents (particularly DMSO, ethyl acetate, DMF) by ¹H NMR or headspace GC. Residual solvent contamination can confound biological assay results, particularly for ERR reporter assays where DMSO itself has minor transcriptional effects at high concentrations.

Independent Verification Approaches

Researchers receiving SLU-PP-332 from commercial sources for use in peer-reviewed studies should consider independent verification. A small aliquot (approximately 0.1-0.5 mg) sent to an independent analytical chemistry laboratory for HPLC-MS reanalysis can confirm purity and identity against a clean reference standard. Several academic chemistry core facilities and commercial contract analytical labs offer this service at modest cost.

An alternative verification approach for laboratories with access to cell-based assay infrastructure is to test the purchased compound in an ERR reporter assay. Stable cell lines expressing ERRα or ERRγ fused to a GAL4 DNA-binding domain with a UAS-luciferase reporter are available from academic depositors and commercial sources. A genuine SLU-PP-332 sample should show dose-dependent luciferase activation with an EC50 consistent with published values (low nanomolar to sub-micromolar range for ERRγ). ^[3]

If a sample fails to activate ERR reporter activity at concentrations where published data would predict a robust response, this is a strong indicator of either incorrect identity (a structurally distinct compound that passed HPLC mass check), significant degradation, or a coformulation issue. For more guidance on interpreting CoAs across compound classes, see our CoA reading guide.

Dosage and Reconstitution

Dose Ranges from Published Rodent Studies

Published studies have used SLU-PP-332 at intraperitoneal or oral gavage doses ranging from approximately 20 mg/kg to 100 mg/kg in mice, with the 50 mg/kg/day oral dose appearing most commonly in the exercise-mimetic literature. ^[1] At 50 mg/kg, a 25-gram C57BL/6 mouse receives 1.25 mg of compound per administration. At 100 mg/kg, the same mouse receives 2.5 mg. These doses are substantially higher on a per-kilogram basis than would be the case for many peptide-based research compounds, and researchers should take note of the total compound quantities required for a multi-mouse, multi-week study.

Worked Dosing Examples

Example 1: Standard mouse study at 50 mg/kg/day

• Mouse weight: 25 g (0.025 kg)
• Target dose: 50 mg/kg
• Dose per mouse: 50 mg/kg x 0.025 kg = 1.25 mg per mouse per day
• Study duration: 4 weeks (28 days), 10 mice per group
• Total compound required (treated group): 1.25 mg x 10 mice x 28 days = 350 mg
• Apollo Peptide Sciences unit provides 12.5 mg (50 capsules x 250 mcg)
• Units required for this study: 350 mg / 12.5 mg per unit = 28 units

This calculation illustrates that the 250mcg capsule format is not ideally matched to the high mg/kg doses used in most published studies for full murine cohort work. Researchers planning multi-week cohort studies at 50+ mg/kg should plan compound procurement accordingly and calculate bulk requirements before study initiation.

Example 2: Lower exploratory dose study at 10 mg/kg/day

• Mouse weight: 25 g
• Target dose: 10 mg/kg
• Dose per mouse: 0.25 mg per day
• Study duration: 2 weeks, 5 mice per group
• Total compound required: 0.25 mg x 5 x 14 = 17.5 mg
• Units required: approximately 2 units (25 mg total)

At the 10 mg/kg level, the 250mcg capsule format is more practical for pilot dose-finding studies, and two units would be sufficient for a small exploratory cohort. This lower dose range has not been as extensively characterized in published literature, making pilot dose-response studies at 5-50 mg/kg a scientifically valuable contribution.

Example 3: In-vitro cell culture applications

For cell-based mechanistic studies (ERR reporter assays, qPCR gene expression in primary myotubes or cardiomyocytes), SLU-PP-332 is typically used at concentrations of 1-10 micromolar in cell culture medium. A single capsule dissolved in DMSO (50 microliters of DMSO per 250 mcg capsule = 5 mg/mL stock, approximately 12.5 mM) provides ample material for dose-response cell experiments. DMSO stocks should be diluted to ≤0.1% final DMSO concentration in cell culture to avoid vehicle toxicity. At 1 micromolar working concentration, 10 mL of treatment medium requires 0.8 microliters of a 12.5 mM stock, illustrating that a single capsule provides hundreds of cell culture treatment wells.

Preparation for Oral Gavage

For oral gavage administration in mice, SLU-PP-332 is typically dissolved in a 0.5% methylcellulose or 10% polyethylene glycol (PEG-400) in water vehicle, which provides sufficient aqueous suspension for accurate volume delivery. The compound's lipophilicity means that aqueous solubility is limited, and sonication followed by vortex mixing is typically required to achieve a uniform suspension. Researchers should verify suspension homogeneity by visual inspection and, for publishable studies, by analytical re-sampling of the dosing vehicle. For detailed vehicle preparation and gavage technique protocols, consult our reconstitution guide and the dosage calculation guide.

Side Effects and Safety

Observations from Preclinical Rodent Studies

In published rodent studies using SLU-PP-332 at doses of 50-100 mg/kg/day for periods of several weeks, no mortality or overt gross toxicity has been reported. Animals maintained normal body weight trajectory (or showed attenuated weight gain in DIO models), continued normal food and water intake, and showed no behavioral abnormalities attributable to compound treatment. ^[1]

Organ weight analysis in sacrifice studies has not revealed significant differences in liver, kidney, spleen, or heart weights in treated versus vehicle control animals at the doses and durations studied. Serum chemistry panels (ALT, AST, creatinine, BUN) did not show evidence of hepatotoxicity or nephrotoxicity at reported doses, though this should not be extrapolated to higher doses or longer treatment durations that have not been formally studied. ^[2]

Theoretical Safety Concerns

Several theoretical safety considerations merit attention for researchers designing protocols. ERRα is expressed in the liver and drives both fatty acid oxidation and gluconeogenic gene programs. Prolonged maximal activation of hepatic ERRα might theoretically perturb hepatic glucose output in ways that could interact with carbohydrate metabolism in diabetic model animals or fasted animals. Researchers studying metabolic disease should design studies with appropriate fasting-state and fed-state metabolite panels to detect any unexpected hepatic metabolic effects.

ERRγ's role in the heart and its involvement in the cardiac metabolic switch means that researchers using SLU-PP-332 in cardiac disease models should include electrocardiographic monitoring and echocardiography as safety endpoints, not only as efficacy endpoints, to detect any pro-arrhythmic or structural effects that might emerge from pharmacological ERR activation in the context of pathological cardiac remodeling.

The theoretical concern around ERR cross-talk with estrogen receptor signaling has been addressed in published selectivity studies, which confirm minimal activity at ERα and ERβ. ^[3] This reduces but does not eliminate concern about potential reproductive hormonal effects in long-term studies. Researchers using female animal models should include uterine weight and ovarian histology as safety endpoints in any study exceeding four weeks of treatment.

What Is Unknown

No published data exists on SLU-PP-332 genotoxicity, reproductive toxicity, developmental toxicity, carcinogenicity, immunotoxicity, or chronic toxicity beyond the multi-week rodent studies described above. The compound should be treated as a novel chemical entity with an incomplete safety dossier, appropriate safety precautions should be applied in laboratory handling (lab coat, nitrile gloves, adequate ventilation), and any animal study using it should be conducted under full IACUC oversight.

How It Compares

Positioning SLU-PP-332 Against PPARδ Agonists

GW501516 (Cardarine) was perhaps the most prominent predecessor in the exercise-mimetic compound space, and its comparison to SLU-PP-332 is instructive. GW501516 acts through PPARδ rather than ERRs, activating a partially overlapping but distinct gene program that emphasizes fatty acid oxidation in skeletal muscle. Critically, rodent carcinogenicity studies with GW501516 showed dramatically accelerated tumor formation across multiple tissue types, which led to the termination of its clinical development program. ^[11] SLU-PP-332's mechanism does not share the PPARδ pathway and has not shown carcinogenicity signals in published reports, though the compound's carcinogenicity has not been formally tested in the two-year rodent bioassay format used in pharmaceutical toxicology.

The receptor selectivity difference is significant for research design: researchers who want to specifically probe ERR-dependent mitochondrial gene regulation without the PPARδ confound should choose SLU-PP-332 over GW501516 on mechanistic grounds alone, independent of the safety concerns associated with GW501516.

Positioning Against AMPK Activators

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is a well-validated AMPK activator that has been used extensively in exercise mimetic research and has some human pharmacokinetic data. ^[12] AICAR acts upstream of ERRs through AMPK-mediated phosphorylation of PGC-1α, which then engages ERRα and ERRγ to drive mitochondrial gene programs. In this sense, AICAR and SLU-PP-332 converge on similar downstream transcriptional outputs but act at different points in the signaling cascade. AICAR offers the advantage of a longer published literature and some human data, while SLU-PP-332 offers more direct ERR target engagement, oral bioavailability, and avoidance of AMPK's many off-target effects on cellular energy sensing. Researchers may find combination protocols using both compounds useful for mechanistic dissection of AMPK-dependent versus AMPK-independent ERR activation.

Where to Buy

Apollo Peptide Sciences is the primary vendor we have reviewed for SLU-PP-332 in the 250mcg capsule format. The vendor provides HPLC purity data and batch certificates with their product listings, which represents an appropriate baseline for research chemical documentation. Researchers can view the complete product listing, available batch documentation, and vendor specifications at the SLU-PP-332 product page.

When evaluating any supplier for SLU-PP-332, researchers should apply the following minimum criteria in addition to the CoA checklist described in the Purity and Verification section:

Batch-specific documentation: Every purchase should be traceable to a specific lot number with associated test data. Vendors who provide generic or undated CoAs for all stock should be deprioritized.

Identity confirmation by MS: As described above, HPLC alone is not sufficient for identity confirmation of a non-standard research chemical. Vendors who provide mass spectrometry data alongside HPLC chromatograms demonstrate a higher level of analytical commitment.

Accessible customer support: For a compound where the research literature is still relatively limited, the ability to ask technical questions of vendor staff and receive informed responses is valuable. Suppliers who cannot provide basic information about their manufacturing source or testing methodology should be treated with caution.

Cold storage and shipping practices: While SLU-PP-332 in capsule form has reasonable ambient stability, vendors who ship thermally sensitive compounds with ice packs and temperature-controlled packaging demonstrate care for product integrity that is worth factoring into supplier selection. See our comprehensive supplier guide for detailed evaluation frameworks.

For the specific Apollo Peptide Sciences SLU-PP-332 listing reviewed here, the price of $85.00 for 50 capsules (250mcg each, 12.5mg total) positions the product at a moderate price point for a research chemical of this specificity. Researchers should calculate total compound needs for their full study protocol before purchasing, given the high mg/kg dose requirements for in-vivo studies discussed in the Dosage section.

Open Research Questions

The SLU-PP-332 literature, while compelling in its consistency around skeletal muscle and cardiac effects, leaves numerous important questions unanswered that represent genuine opportunities for novel research contribution.

Dose-response characterization at lower doses: Published studies have clustered around 50-100 mg/kg doses in mice. Whether meaningful ERR target gene activation occurs at 5-20 mg/kg, what the minimum effective dose is, and whether there is an inverted-U dose-response relationship (possible if maximal receptor activation produces feedback downregulation) are all uncharacterized. Systematic dose-finding studies would substantially strengthen the compound's research utility and help rationalize the high doses currently used.

Female animal data: Nearly all published SLU-PP-332 studies have used male mice. Given ERRα's well-documented sexual dimorphism in metabolic gene regulation (females show higher basal ERRα activity in some tissues, partly due to estrogen-ERRα cross-talk), the pharmacodynamic response to SLU-PP-332 in female animals may differ substantially from male animals. ^[13] Studies using female mice, particularly in metabolic disease and longevity contexts, are needed.

Long-term safety and tolerability: Multi-week studies have not shown overt toxicity, but formal 13-week or 26-week GLP (good laboratory practice) toxicology studies in rodents have not been published. Before SLU-PP-332 can be considered for any translational application, a formal toxicological characterization will be necessary.

CNS pharmacodynamics: ERRβ and ERRγ are expressed in neurons, and the compound penetrates the CNS. Whether it produces measurable cognitive, behavioral, or neuroprotective effects in validated CNS research models has not been systematically studied. This is an open area where researchers with access to behavioral neuroscience platforms could make a meaningful contribution.

Combination with exercise training: The exercise-mimetic hypothesis predicts that SLU-PP-332 would either synergize with actual exercise training (by further amplifying the same transcriptional program) or potentially show diminishing returns (if ERR signaling is already maximally activated by exercise). No published study has examined the compound in exercising versus sedentary conditions within the same study. ^[14]

Aging biology and lifespan data: As described in the Research section, the longevity-relevant data are currently biomarker-based. Formal lifespan studies, ideally with NIA Interventions Testing Program (ITP) style multi-site replication, would be necessary to make strong claims about lifespan extension. Whether SLU-PP-332 would qualify for NIA-ITP testing is a question the longevity research community could meaningfully address.

Pharmacological Context: ERR Biology in the Larger Metabolic Signaling Network

Understanding SLU-PP-332's pharmacology requires situating ERR receptors within the broader hierarchical network of metabolic signaling. The central signaling axis relevant to this compound is: energy stress (exercise, calorie restriction, fasting) activates AMPK, which phosphorylates and activates PGC-1α, which then binds to ERRα and ERRγ to drive mitochondrial gene programs. Simultaneously, SIRT1 (activated by elevated NAD+ during energy stress) deacetylates PGC-1α, enhancing its activity and ERR co-activation. This AMPK-SIRT1-PGC-1α-ERR axis represents the molecular core of the exercise and calorie restriction response in oxidative tissues. ^[9]

SLU-PP-332 operates at the ERR node of this network, downstream of AMPK and SIRT1 but upstream of the final transcriptional output. This positioning has both advantages and limitations. The advantage is that it bypasses the upstream signaling steps that may be difficult to activate pharmacologically without broad metabolic side effects (AMPK activation, for example, affects dozens of cellular processes beyond mitochondrial biogenesis). The limitation is that the compound cannot replicate the full complexity of the exercise response, which involves not only ERR-mediated transcriptional changes but also mechanical load sensing, lactate signaling, myokine secretion, and epigenetic remodeling that occur in parallel and in concert with ERR activation.

The nuclear receptor field has a long history of compounds that produced remarkable effects in preclinical models but faced unexpected challenges in translation to human physiology. The thiazolidinedione class (PPARγ agonists) remains the most cautionary example: potent insulin sensitizers in rodents that proved effective in humans but introduced cardiovascular and bone risks that were not predicted from rodent data. Researchers approaching SLU-PP-332 should maintain this historical perspective, recognizing that the rodent-to-human translational gap in nuclear receptor pharmacology is real and not yet characterized for this compound. ^[15]

The ERR receptors themselves have human genetic data supporting their metabolic relevance. Genome-wide association studies (GWAS) have identified variants in ESRRA (the gene encoding ERRα) associated with body mass index, type 2 diabetes risk, and exercise capacity in human populations. ^[16] This genetic validation of the target in humans is an encouraging indicator that the pathway engaged by SLU-PP-332 is physiologically relevant in human metabolism, even if the compound's human pharmacology remains unexplored.

FAQ